Study type: In vivo/preclinical · Status: Verified against declared source

Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis

2018

Study scale: Corneas from B6 animals treated with PBS, Tβ4, ciprofloxacin, or Tβ4 + ciprofloxacin were collected at 5 days p.i.

Abstract only: Open source record

Product or molecular entity relationships

Thymosin Beta-4 (TB500): Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Total RNA was isolated from individual whole corneas at 3 and 5 days p.i.

Scale or participants

Corneas from B6 animals treated with PBS, Tβ4, ciprofloxacin, or Tβ4 + ciprofloxacin were collected at 5 days p.i.

Key findings

With increasing multidrug resistance and contraindication for corticosteroid use, the goal of this study was to develop thymosin beta-4 (Tβ4) as an adjunctive therapy to antibiotics for the treatment of bacterial keratitis that effectively promotes enhanced wound healing, host defense, and inflammation resolution.

Limitations and uncertainty

Viable bacteria were determined by direct plate counts from infected corneas at 5 days p.i., as shown in Figure 3A.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.